Search Results

Exothera SA announced a collaboration with LogicBio® Therapeutics and Polyplus-transfection® SA. for the development of a highly scalable AAV manufacturing platform with a capacity from 200 L to 2,000 L.

The global cell transfection market is expected to expand at a remarkable CAGR during the forecast period from 2023 to 2032.

Polyplus-transfection® SA, a biotechnology company that develops and sells innovative solutions for the delivery of nucleic acids in research, bioproduction and therapeutics, today announces the launch of jetOPTIMUS(R), a new reagent for powerful nanoparticle DNA transfection.

Polyplus-transfection® SA, a biotechnology company that develops and sells innovative solutions for the delivery of nucleic acids in research, bioproduction and therapeutics, today announces the launch of PEIpro(R)-GMP, a transfection reagent designed for the clinical and commercial lentivirus and adeno-associated virus (AAV) production of cell & gene therapies.

BioCentriq, Inc announced today that they’ve completed a study designed to test transfection of T-cells with GFP mRNA for evaluation of cell viability, transfection efficiency, and post transfection growth using Kytopen’s Flowfect® technology.

Transfection involves the conscious introduction of nucleic acid molecules into eukaryotic cells.

Transfection involves the conscious introduction of nucleic acid molecules into eukaryotic cells. Some of the most common examples of transfection include introducing DNA plasmids possessing gene inserts for expression and small interfering RNA.

New GMP conditioning of PEIpro-GMP designed to support clinical phase and commercialization stages of production

This webinar, tailored for scientists in academia, biotech, and pharma, explores how intelligent mRNA designs can reduce experimental workloads and improve mRNA performance and efficacy.